State-of-the-Art Hepatitis Research in 2022

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Hepatitis Virus Vaccines".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 1604

Special Issue Editor


E-Mail Website
Guest Editor
Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, The Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
Interests: hepatitis viruses (A, B, C, D, and E); experimental system; host immune responses; vaccines; pathogenesis

Special Issue Information

Dear Colleagues,

In recent decades, numerous studies focused on the virology, epidemiology, immunology, genetics, molecular biology, natural history, pathogenesis, current drug treatment, and new drug development in hepatitis research have strengthened our knowledge in this field. Such research provides the chance to identify and develop vaccines and treatments or cure viral hepatitis infections. Therefore, we welcome contributions to this Special Issue of Viruses, “State-of-the-Art Hepatitis Research in 2022”. The aim is to provide comprehensive information on all aspects of hepatitis research. Contributions to this Special Issue will advance our knowledge of hepatitis induced by virus infections and provide a better understanding of this serious human pathogen. This Special Issue will bring together original research papers and review manuscripts on hepatitis research with a focus on acute/chronic viral replication, pathogenesis, immune responses, vaccine development, hepatic disease, and antiviral treatments in viral hepatitis research.

Dr. Youkyung Choi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute infection
  • chronic infection
  • virus replication
  • pathogenesis
  • immune responses
  • vaccine development
  • antiviral treatment
  • in vitro and in vivo experimental infection systems
  • host factors and biomarkers in viral hepatitis infections

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 4332 KiB  
Article
Specific Binding and Endocytosis of Liposomes to HEK293T Cells via Myrisoylated Pre-S1 Peptide Bound to Sodium Taurocholate Cotransporting Polypeptide
by Shuji Hinuma, Kazuyo Fujita and Shun’ichi Kuroda
Vaccines 2022, 10(12), 2050; https://doi.org/10.3390/vaccines10122050 - 30 Nov 2022
Viewed by 1255
Abstract
(1) Background: Sodium taurocholate cotransporting polypeptide (NTCP) functions as a key receptor for the hepatitis B virus (HBV) infection. Analyzing HBV and NTCP interaction is an important issue not only for basic research but also for the development of anti-HBV therapeutics. We developed [...] Read more.
(1) Background: Sodium taurocholate cotransporting polypeptide (NTCP) functions as a key receptor for the hepatitis B virus (HBV) infection. Analyzing HBV and NTCP interaction is an important issue not only for basic research but also for the development of anti-HBV therapeutics. We developed here a novel model system to analyze the interaction of NTCP with liposomes instead of HBV. (2) Methods: Liposomal binding and endocytosis through NTCP in HEK293T cells were achieved by serial treatments of HEL293T cells transiently expressing NTCP-green fluorescence protein (GFP) fusion protein with a synthetic biotinylated pre-S1 peptide (Myr47-Bio) and streptavidin (SA) complex (i.e., Myr47-Bio+SA) followed by biotinylated liposomes. By this procedure, binding of [biotinylated liposomes]-[Myr47-Bio+SA]-[NTCP-GFP] was formed. (3) Results: Using this model system, we found that liposomal binding to NTCP on the cell surface via Myr47-Bio+SA was far more efficient than that to scavenger receptor class B type 1 (SR-B1). Furthermore, liposomes bound to cell surface NTCP via Myr47-Bio+SA were endocytosed into cells after cells were cultured at 37 °C. However, this endocytosis was suppressed by 4 °C or cytochalasin B treatment. (4) Conclusions: This model system will be useful for not only analyzing HBV entry mechanisms but also screening substances to prevent HBV infection. Full article
(This article belongs to the Special Issue State-of-the-Art Hepatitis Research in 2022)
Show Figures

Figure 1

Back to TopTop